Antivirals Committee To Discuss Epivir HBV But Not Sustiva And Ziagen
Executive Summary
FDA's Antiviral Drugs Advisory Committee will discuss Glaxo Wellcome/BioChem's Epivir HBV (lamivudine) for the treatment of chronic hepatitis B viral infection on Oct. 6 at the Holiday Inn, Silver Spring Md., beginning at 8:30 a.m.